NCT06524544 2026-03-18
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
National Cancer Institute (NCI)
Phase 3 Recruiting
National Cancer Institute (NCI)
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
BeOne Medicines
Hoffmann-La Roche
Mabwell (Shanghai) Bioscience Co., Ltd.
RemeGen Co., Ltd.
National Cancer Institute (NCI)
Shanghai Junshi Bioscience Co., Ltd.